{
    "clinical_study": {
        "@rank": "85582", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (definitive therapy)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines.  The 5 chemo backbone options are:\ndoxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel\ndocetaxel plus cyclophosphamide\nsingle-agent paclitaxel\ndocetaxel plus carboplatin\nfluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel"
            }, 
            {
                "arm_group_label": "Arm II (definitive therapy, trastuzumab)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:\ndoxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel\ndocetaxel plus cyclophosphamide\nsingle-agent paclitaxel\ndocetaxel plus carboplatin\nfluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel\nPatients will also receive trastuzumab IV over 30-90 minutes for 52 weeks starting such that there is a minimum of 8 weeks of overlap with the standard of care chemotherapy. Trastuzumab may be given weekly, every 2 weeks, or every 3 weeks while overlapping with standard of care chemotherapy.  Trastuzumab will be given every 3 weeks after all standard of care chemotherapy has concluded. Treatment continues in the absence of disease progression or unacceptable toxicity."
            }
        ], 
        "brief_summary": {
            "textblock": "This phase II trial studies  the efficacy of  trastuzumab treatment in  breast cancer\n      patients with stage II-III human epidermal growth factor receptor 2 (HER2)-negative tumors\n      and HER2-expressing bone marrow disseminated tumor cells. Administering targeted trastuzumab\n      therapy to these patients may result in the elimination of HER2 expressing disseminated\n      tumor cells and improved disease free survival."
        }, 
        "brief_title": "Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells", 
        "completion_date": {
            "#text": "September 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Pre-Registration Inclusion Criteria:\n\n          -  Histologically confirmed HER2-negative primary invasive ductal or invasive lobular\n             breast carcinoma.  For patients enrolling for neoadjuvant treatment, diagnosis must\n             be clinical stage II or III; for patients enrolling for adjuvant treatment, diagnosis\n             must be pathologic stage IIA to IIIC.  Standard HER2 testing will be performed in the\n             surgical specimen at Washington University according to the standard of care in the\n             Department of Pathology.  A HER2-negative primary breast cancer sample from a patient\n             eligible for randomization should have a HER2 IHC score of 0 or  1+ Those patients\n             with IHC score of 2+ should be HER2 FISH-negative in standard testing.  Patient will\n             have undergone staging studies including a CT of the chest/abdomen/pelvis and bone\n             scan and/or PET scan either prior to the initiation of treatment or prior to entry\n             into the trial. In addition, patients with non-metastatic, HER2-negative, recurrent\n             tumors who need chemotherapy are eligible.\n\n          -  Planning to receive best practice adjuvant or neoadjuvant chemotherapy according to\n             institutional guidelines. Adjuvant tamoxifen or aromatase inhibitors treatment will\n             be allowed for hormone receptor-positive patients.  Patients who have failed\n             neoadjuvant endocrine therapy will also be eligible.\n\n          -  At least 18 years old.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status \u2264 1.\n\n          -  Patient (or legally authorized representative) must be able to understand and willing\n             to sign a written informed consent document.\n\n        Pre-Registration Exclusion Criteria:\n\n          -  Prior chemotherapy for this cancer (excluding initiation of best practice\n             chemotherapy to be given as standard of care as described in this protocol, which may\n             be initiated after the pre-registration bone marrow collection but before final\n             confirmation of eligibility and randomization).\n\n          -  Previous treatment with trastuzumab or any other Her2 targeted therapy.\n\n          -  Presence of an uncontrolled intercurrent illness including, but not limited to,\n             ongoing or active infection, symptomatic congestive heart failure, unstable angina\n             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would\n             limit compliance with study requirements.\n\n        Registration Inclusion Criteria\n\n          -  Presence of bone marrow ERBB2 overexpressing DTCs at the time of diagnosis; bone\n             marrow aspiration will be performed in consented patients to evaluate DTCs following\n             pre-registration provided patients meet all eligibility criteria as described in this\n             section.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status \u2264 1.\n\n          -  Adequate cardiac function as demonstrated by LVEF of >55% performed no more than 4\n             weeks prior to randomization.\n\n          -  Normal organ and marrow function as defined below:\n\n               -  leukocytes \u22653,000/mcL\n\n               -  absolute neutrophil count \u22651,500/mcL\n\n               -  platelets \u2265100,000/mcL\n\n               -  hemoglobin \u2265 10 g/dL\n\n               -  total bilirubin within institutional upper limits of normal unless related to\n                  primary disease\n\n               -  AST(SGOT)/ALT(SGPT) \u22642.0 X institutional upper limit of normal\n\n               -  Creatinine \u2264 1.5  institutional upper limits of normal OR creatinine clearance\n                  \u226560 mL/min/1.73 m2 for patients with creatinine levels above institutional\n                  normal\n\n          -  If a woman of childbearing potential, patient must use two forms of effective\n             contraception for a minimum of 6 months following trastuzumab. Effective methods of\n             birth control include use of established oral, injected, or implanted hormonal\n             methods of birth control, IUD, IUS, and condoms.\n\n        Registration Exclusion Criteria\n\n          -  Evidence of distant metastasis present by CT scan, bone scan, or physical exam.\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to trastuzumab.\n\n          -  Prior chemotherapy for this cancer (excluding initiation of best practice\n             chemotherapy to be given as standard of care described in this protocol, which may be\n             initiated after the pre-registration bone marrow collection but before final\n             confirmation of eligibility and randomization).\n\n          -  History of other malignancy \u2264 5 years previous with the exception of basal cell or\n             squamous cell carcinoma of the skin which were treated with local resection only or\n             carcinoma in situ of the cervix.\n\n          -  Pregnant or breastfeeding.  Patient must have a negative serum pregnancy test \u2264 7\n             days from date of registration (if a woman of childbearing potential).\n\n          -  Clinically important history of active liver disease, including viral or other\n             hepatitis or cirrhosis.\n\n          -  Uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, or hypokalemia defined as\n             less than the lower limit of normal for the institution despite adequate electrolyte\n             supplementation.\n\n          -  Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs\n             resulting in dyspnea at rest."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779050", 
            "org_study_id": "201309084"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm I (definitive therapy)", 
                    "Arm II (definitive therapy, trastuzumab)"
                ], 
                "intervention_name": "Doxorubicin", 
                "intervention_type": "Drug", 
                "other_name": "Adriamycin\u00ae, Rubex\u00ae, Hydroxydaunomycin Hydrochloride, Hydroxydoxorubicin Hydrochloride"
            }, 
            {
                "arm_group_label": "Arm II (definitive therapy, trastuzumab)", 
                "intervention_name": "Trastuzumab", 
                "intervention_type": "Biological", 
                "other_name": "\u2022Herceptin\u00ae"
            }, 
            {
                "arm_group_label": [
                    "Arm I (definitive therapy)", 
                    "Arm II (definitive therapy, trastuzumab)"
                ], 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": "Cytoxan\u00ae, CPM, CTX, CYT"
            }, 
            {
                "arm_group_label": [
                    "Arm I (definitive therapy)", 
                    "Arm II (definitive therapy, trastuzumab)"
                ], 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Abraxane\u00ae, Onxol\u00ae"
            }, 
            {
                "arm_group_label": [
                    "Arm I (definitive therapy)", 
                    "Arm II (definitive therapy, trastuzumab)"
                ], 
                "intervention_name": "Epirubicin", 
                "intervention_type": "Drug", 
                "other_name": "Ellence, Pharmorubicin, Epirubicin ebewe"
            }, 
            {
                "arm_group_label": [
                    "Arm I (definitive therapy)", 
                    "Arm II (definitive therapy, trastuzumab)"
                ], 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxotere, Docefrez"
            }, 
            {
                "arm_group_label": "Arm II (definitive therapy, trastuzumab)", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug", 
                "other_name": "cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), Paraplatin, Paraplatin-AQ"
            }, 
            {
                "arm_group_label": [
                    "Arm I (definitive therapy)", 
                    "Arm II (definitive therapy, trastuzumab)"
                ], 
                "intervention_name": "Fluorouracil", 
                "intervention_type": "Drug", 
                "other_name": "5-FU, Adrucil"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Fluorouracil", 
                "Docetaxel", 
                "Trastuzumab", 
                "Doxorubicin", 
                "Epirubicin", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 15, 2014", 
        "link": {
            "description": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine", 
            "url": "http://www.siteman.wustl.edu"
        }, 
        "location": {
            "contact": {
                "email": "aftr@wudosis.wustl.edu", 
                "last_name": "Rebecca Aft, M.D., Ph.D.", 
                "phone": "314-747-0063"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": [
                {
                    "last_name": "Foluso Ademuyiwa, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mark Watson, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ron Bose, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Matthew Ellis, M.B., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michael Naughton, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Steven Sorscher, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rama Suresh, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Timothy Eberlein, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "William Gillanders, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Julie Margenthaler, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Amy Cyr, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Deb Novack, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Cynthia Ma, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Adel Tabchy, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells", 
        "overall_contact": {
            "email": "aftr@wudosis.wustl.edu", 
            "last_name": "Rebecca Aft, M.D., Ph.D.", 
            "phone": "314-747-0063"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Rebecca Aft, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Rate for patients receiving trastuzumab in addition to standard chemotherapy and for patients receiving standard chemotherapy alone; calculated using Cox proportional hazards models", 
                "measure": "Recurrence Rate at 3 years", 
                "safety_issue": "No", 
                "time_frame": "3 years after completion of standard chemotherapy and surgery"
            }, 
            {
                "description": "Death rate at 3 years Rate for patients receiving trastuzumab in addition to standard chemotherapy and for patients receiving standard chemotherapy alone; calculated using Cox proportional hazards models 3 years after completion of definitive therapy (3.5 years) No\nSecondary Outcome Measures Title Description Time Frame Safety Issue? Elimination of ERBB2 expressing bone marrow DTCs  Bone marrow samples collected at baseline and 14 months later; Fisher's exact test will be used to compare the proportion of patients who eliminate ERBB2-positive DTCs from BM in the two study arms. 14 months  No", 
                "measure": "Death rate at 3 years", 
                "safety_issue": "No", 
                "time_frame": "3 years after completion of definitive therapy"
            }
        ], 
        "reference": [
            {
                "PMID": "23129172", 
                "citation": "Siddappa CM, Watson MA, Pillai SG, Trinkaus K, Fleming T, Aft R. Detection of disseminated tumor cells in the bone marrow of breast cancer patients using multiplex gene expression measurements identifies new therapeutic targets in patients at high risk for the development of metastatic disease. Breast Cancer Res Treat. 2013 Jan;137(1):45-56. doi: 10.1007/s10549-012-2279-y. Epub 2012 Nov 6."
            }, 
            {
                "PMID": "21717141", 
                "citation": "Rack B, J\u00fcckstock J, G\u00fcnthner-Biller M, Andergassen U, Neugebauer J, Hepp P, Schoberth A, Mayr D, Zwingers T, Schindlbeck C, Friese K, Janni W. Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Arch Gynecol Obstet. 2012 Feb;285(2):485-92. doi: 10.1007/s00404-011-1954-2. Epub 2011 Jun 30."
            }, 
            {
                "PMID": "17262082", 
                "citation": "Vincent-Salomon A, Pierga JY, Couturier J, d'Enghien CD, Nos C, Sigal-Zafrani B, Lae M, Fr\u00e9neaux P, Di\u00e9ras V, Thi\u00e9ry JP, Sastre-Garau X. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer. 2007 Feb 26;96(4):654-9. Epub 2007 Jan 30."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779050"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Bone marrow samples collected at baseline and 14 months later; Fisher's exact test will be used to compare the proportion of patients who eliminate ERBB2-positive DTCs from BM in the two study arms.", 
            "measure": "Elimination of ERBB2 overexpressing bone marrow DTCs", 
            "safety_issue": "No", 
            "time_frame": "14 months"
        }, 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}